AURA
Aura Biosciences, Inc.
NASDAQ · USHealthcareBiotechnology
$6.82-2.43%
Price as of Jul 20, 2026
AURA financials
Aura Biosciences, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $1.3M | $0.00 |
| Gross profit | $0.00 | $0.00 | -$1.3M | $0.00 |
| Operating expenses | $112.8M | $96.1M | $83.7M | $60.3M |
| Operating income | -$112.8M | -$96.1M | -$85.0M | -$60.3M |
| Net income | -$106.2M | -$86.9M | -$76.4M | -$58.8M |
| EBITDA | -$105.0M | -$85.6M | -$75.0M | -$57.6M |
| Basic EPS | $-1.76 | $-1.75 | $-1.93 | $-1.96 |
| Diluted EPS | $-1.76 | $-1.75 | $-1.93 | $-1.96 |
| Balance sheet | ||||
| Cash & equivalents | $59.5M | $31.7M | $41.1M | $121.6M |
| Total assets | $169.4M | $182.5M | $255.1M | $223.9M |
| Total liabilities | $32.5M | $30.5M | $29.2M | $28.4M |
| Stockholders’ equity | $136.9M | $152.0M | $225.8M | $195.6M |
| Total debt | $17.4M | $18.8M | $19.6M | $20.9M |
| Net debt | -$42.1M | -$12.9M | -$21.5M | -$100.7M |
| Cash flow | ||||
| Operating cash flow | -$84.7M | -$79.8M | -$63.8M | -$54.6M |
| Capital expenditure | -$447.0K | -$1.3M | -$709.0K | -$1.1M |
| Free cash flow | -$85.2M | -$81.1M | -$64.6M | -$55.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |